Respiratory Syncytial Virus (RSV) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Enanta, ReViral, Pfizer, Sanofi, BioComo

 Breaking News
  • No posts were found

Respiratory Syncytial Virus (RSV) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Enanta, ReViral, Pfizer, Sanofi, BioComo

November 07
21:57 2023
Respiratory Syncytial Virus (RSV) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Enanta, ReViral, Pfizer, Sanofi, BioComo
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Respiratory Syncytial Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Respiratory Syncytial Virus Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Respiratory Syncytial Virus Market. 

The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial, regulatory, and Respiratory Syncytial Virus clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Respiratory Syncytial Virus drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Respiratory Syncytial Virus Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Respiratory Syncytial Virus treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Respiratory Syncytial Virus therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Respiratory Syncytial Virus companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Respiratory Syncytial Virus drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Respiratory Syncytial Virus therapeutic market.

Respiratory Syncytial Virus Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Respiratory Syncytial Virus (RSV). Currently, GlaxoSmithKline is leading the therapeutics market with its Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage of clinical development.

Respiratory Syncytial Virus Companies Actively Working in the Therapeutic Market Include:

GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and many others.

Emerging and Marketed Respiratory Syncytial Virus Drugs Covered in the Report Include:

  • GSK3844766A: GlaxoSmithKline

  • Nirsevimab (MEDI-8897): MedImmune

  • Sisunatovir: ReViral

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Respiratory Syncytial Virus Companies Working in the Market @

Analysis of Emerging Respiratory Syncytial Virus Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Respiratory Syncytial Virus (RSV) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical.

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Respiratory Syncytial Virus Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Respiratory Syncytial Virus Treatment Patterns

4. Respiratory Syncytial Virus – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Respiratory Syncytial Virus Late Stage Products (Phase-III)

7. Respiratory Syncytial Virus Mid-Stage Products (Phase-II)

8. Respiratory Syncytial Virus Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Respiratory Syncytial Virus Discontinued Products

13. Respiratory Syncytial Virus Product Profiles

14. Major Respiratory Syncytial Virus Companies in the Market

15. Key Products in the Respiratory Syncytial Virus Therapeutics Segment

16. Dormant and Discontinued Products

17. Respiratory Syncytial Virus Unmet Needs

18. Respiratory Syncytial Virus Future Perspectives

19. Respiratory Syncytial Virus Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Oncolytic Virus Cancer Therapy Market

“Oncolytic Virus Cancer Therapy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Oncolytic Virus Cancer Therapy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Oncolytic Virus Cancer Therapy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles


December 2023